Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Immvira Bioscience Files for Hong Kong IPO to Advance Novel Oncolytic Immunotherapy and Engineered Exosome Pipeline

Fineline Cube Jul 17, 2026
Company Deals

Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression

Fineline Cube Jul 17, 2026
Company Deals

Jasper Therapeutics Completes Acquisition of Kira Pharmaceuticals in All-Stock Transaction, Secures $132M Private Placement for Complement Therapies Pipeline

Fineline Cube Jul 17, 2026
Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Fineline Cube Jul 16, 2026
Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Fineline Cube Jul 16, 2026
Policy / Regulatory

China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs

Fineline Cube Jul 16, 2026
Company Drug

CSPC Pharmaceutical Launches Phase III Trial of B7-H3-Targeting ADC SYS 6043 for Platinum-Resistant Ovarian Cancer

Fineline Cube Jul 17, 2026
Company Drug

CSPC Pharmaceutical Launches Phase II Trial of Albumin-Bound Sirolimus for Rare Vascular Tumor Epithelioid Hemangioendothelioma

Fineline Cube Jul 17, 2026
Company Drug

Daiichi Sankyo, AstraZeneca Secure FDA Approval for Datroway in Triple-Negative Breast Cancer After Phase III TROPION-Breast02 Success

Fineline Cube May 25, 2026

Daiichi Sankyo Company, Limited (TYO: 4568) and AstraZeneca PLC (NYSE: AZN) announced U.S. Food and...

Company Drug

Novo Nordisk Secures CHMP Positive Opinion for Wegovy 7.2 mg Single-Dose Pen and Oral Semaglutide in EU Obesity Treatment

Fineline Cube May 25, 2026

Novo Nordisk A/S (NYSE: NVO) announced that the Committee for Medicinal Products for Human Use...

Company Medical Device

Hangzhou Diagens Secures NMPA Category III Approval for AI AutoVision Chromosome Karyotyping System

Fineline Cube May 25, 2026

Hangzhou Diagens Biotechnology Co., Ltd. (HKG: 2526) announced it has received Category III medical device...

Company Drug

Biogen, Denali Terminate Parkinson’s Drug BIIB122 After Phase IIb LUMA Study Failure

Fineline Cube May 25, 2026

Biogen Inc. (NASDAQ: BIIB) and Denali Therapeutics Inc. (NASDAQ: DNLI) jointly announced the termination of...

Company Drug

Junshi Biosciences Secures NMPA Approval for Loqtorzi Combination Therapy in HER2-Expressing Urothelial Carcinoma

Fineline Cube May 24, 2026

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) announced that China’s National Medical Products...

Company Drug

Shanghai Henlius Biotech Secures Australian TGA Approval for Phase I Trial of HLX3902 Trispecific T-Cell Engager in Prostate Cancer

Fineline Cube May 24, 2026

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that Australia’s Therapeutic Goods Administration (TGA) has granted...

Company Drug

Shanghai Henlius Biotech Secures NMPA Approval for Phase I Trial of HLX48 Bispecific ADC in Advanced Solid Tumors

Fineline Cube May 24, 2026

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that China’s National Medical Products Administration (NMPA) has...

Company Drug

Sino Biopharmaceutical Presents Positive Phase III and II Data for M701 Bispecific Antibody at ASCO 2026

Fineline Cube May 24, 2026

Sino Biopharmaceutical Ltd (HKG: 1177) announced positive results from its Phase III and Phase II...

Company Drug

Qyuns Therapeutics and Huadong Medicine Secure NMPA Approval for Stelara Biosimilar HDM3001-2/QX001S in Crohn’s Disease

Fineline Cube May 24, 2026

Qyuns Therapeutics (HKG: 2509) announced that HDM3001-2/QX001S, a biosimilar to Johnson & Johnson’s autoimmune therapy...

Company Drug

3D Medicines Enrolls First Patient in Pivotal Phase III Trial of Envafolimab for Resectable NSCLC

Fineline Cube May 24, 2026

3D Medicines (HKG: 1244) announced the enrollment of the first patient in a Phase III...

Company

Zai Lab Announces Executive Leadership Reshuffle as COO Josh Smiley Steps Down After Nearly Four Years

Fineline Cube May 23, 2026

Zai Lab (NASDAQ: ZLAB; HKG: 9688) announced a significant executive leadership reshuffle, with President and...

Company Drug

Allergan Aesthetics Secures CHMP Positive Opinion for Boey (TrenibotulinumtoxinE) in Glabellar Lines Treatment Across European Economic Area

Fineline Cube May 23, 2026

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that the European Medicines Agency’s (EMA) Committee...

Company Drug

Lupeng Pharma Enrolls First Patient in Global Phase 3 ROCKET-CLL Trial of Fourth-Gen BTK Inhibitor Rocbrutinib vs. Pirtobrutinib

Fineline Cube May 23, 2026

Lupeng Pharmaceutical Ltd. announced the enrollment of the first patient in its global Phase 3...

Company Drug

Eli Lilly’s Retatrutide Delivers Breakthrough Weight Loss Results in Phase 3 TRIUMPH-1 Trial for Obesity Treatment

Fineline Cube May 22, 2026

Eli Lilly and Company (NYSE: LLY) announced positive topline results from the TRIUMPH-1 Phase 3...

Company Drug

Merck KGaA Launches Phase III PROCEADE-CRC-03 Trial for First-in-Class CEACAM5 ADC Precemtabart Tocentecan in Metastatic Colorectal Cancer

Fineline Cube May 22, 2026

Merck KGaA (ETR: MRK) announced the initiation of the Phase III PROCEADE-CRC-03 study, evaluating the...

Company Drug

Astellas and MSD’s PADCEV-Keytruda Combination Receives Positive CHMP Opinion for Muscle-Invasive Bladder Cancer in EU

Fineline Cube May 22, 2026

Astellas Pharma Inc. (TYO: 4503) announced that the Committee for Medicinal Products for Human Use...

Company Drug

Hansoh Pharma’s HS-10504 Receives NMPA Breakthrough Therapy Designation for Fourth-Generation EGFR Inhibitor in Resistant NSCLC

Fineline Cube May 22, 2026

Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced that China’s Center for Drug Evaluation (CDE)...

Company Drug

Bayer’s Kerendia Receives FDA Priority Review for Expanded Indication in Type 1 Diabetes-Associated Chronic Kidney Disease

Fineline Cube May 22, 2026

Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has accepted...

Company Deals

Gilead Sciences Launches Five-Year WHO Partnership to Accelerate Elimination of Visceral Leishmaniasis in High-Burden Regions

Fineline Cube May 22, 2026

Gilead Sciences, Inc. (NASDAQ: GILD) announced a five-year strategic collaboration with the World Health Organization...

Company Deals

Johnson & Johnson Partners with Abu Dhabi DOH to Launch Global Surgical Intelligence Network Powered by Polyphonic Platform

Fineline Cube May 22, 2026

Johnson & Johnson (J&J, NYSE: JNJ) announced a strategic alliance with the Abu Dhabi Department...

Posts pagination

1 … 26 27 28 … 696

Recent updates

  • CSPC Pharmaceutical Launches Phase III Trial of B7-H3-Targeting ADC SYS 6043 for Platinum-Resistant Ovarian Cancer
  • CSPC Pharmaceutical Launches Phase II Trial of Albumin-Bound Sirolimus for Rare Vascular Tumor Epithelioid Hemangioendothelioma
  • Immvira Bioscience Files for Hong Kong IPO to Advance Novel Oncolytic Immunotherapy and Engineered Exosome Pipeline
  • Abbott Reports Strong Q2 2026 Results with 12.2% Revenue Growth Driven by Diagnostics Surge and Medical Device Innovation
  • Hengrui’s HRS9531 Dual GIPR/GLP-1R Agonist Advances to Phase III for Obesity with Knee Osteoarthritis, Expanding Metabolic Disease Portfolio
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CSPC Pharmaceutical Launches Phase III Trial of B7-H3-Targeting ADC SYS 6043 for Platinum-Resistant Ovarian Cancer

Company Drug

CSPC Pharmaceutical Launches Phase II Trial of Albumin-Bound Sirolimus for Rare Vascular Tumor Epithelioid Hemangioendothelioma

Company Deals

Immvira Bioscience Files for Hong Kong IPO to Advance Novel Oncolytic Immunotherapy and Engineered Exosome Pipeline

Company

Abbott Reports Strong Q2 2026 Results with 12.2% Revenue Growth Driven by Diagnostics Surge and Medical Device Innovation

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.